Advanced Oxford, the organisation for Oxfordshire’s innovation businesses, welcomes Evotec into its membership.
Advanced Oxford’s goal is to make the Oxford region the most fertile innovation economy in the UK; a globally connected cluster, recognised as the best place to start, grow and locate innovative and knowledge-based businesses.
Evotec, a leading, globally operating life sciences company, joins Advanced Oxford as the not-for-profit membership group prepares to kick off its next research project examining the skills and talent pipeline for innovation within the Oxford region. Acquiring and retaining talent is a key issue for Evotec, which has recently expanded their presence at its Milton Park site, the “Dorothy Crowfoot Hodgkin Campus”. Evotec recently took additional office and laboratory space at Milton Park, in addition to new space it took at 90 Park Drive in September 2020. Evotec is now one of the largest occupiers on Milton Park and expects to see further growth in the Oxfordshire team over the course of 2021 and beyond.
Sarah Haywood, Advanced Oxford’s Managing Director said, “We are delighted to welcome Evotec into our membership. Advanced Oxford is committed to the development of the innovation ecosystem and Evotec is an important STEM-based company within Oxfordshire. It is exciting to see Evotec’s commitment to the region as they grow their team and footprint at Milton Park. Evotec’s experience in integrated drug discovery and development, their collaborations with industry, academia and venture capital, as well as their interests in data, AI, machine learning will bring valuable perspectives to our current work on skills, as well as our other activities.”
Christophe Muller, PhD, head of Evotec’s Milton Park site and EVP global head of business development, said “We are excited to join Advanced Oxford as we share their vision for the Oxfordshire region as a dynamic and high-quality environment for life science innovation. With the expansion of our ‘Dorothy Crowfoot Hodgkin Campus’ into a fully integrated R&D Centre, Evotec has laid the foundation for further long-term growth with the key purpose of discovering and developing future treatments options to patients across many disease areas. We very much look forward to working together with Advanced Oxford to continue promoting the Oxfordshire region.”
Christophe Muller, Head of Evotec’s Milton Park site, pictured with Philip Campbell, from Milton Park
About Evotec SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women’s health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.
